First successful treatment of leukemia with CAR-T immune cell therapy

The first patient in Vietnam to be successfully treated with CAR-T cell therapy was a 12-year-old patient with B-cell acute lymphoblastic leukemia, a high-risk group.

This is the information shared by Professor, Doctor, Doctor Phu Chi Dung, Director of Ho Chi Minh City Blood Transfusion - Hematology Hospital at 3 conferences taking place simultaneously: 8th Vietnam Blood Transfusion - Hematology Conference, 8th Vietnam - France Expanded Blood Transfusion - Transplantation - Cell Therapy Conference and 30th Asia - Pacific Blood and Bone Marrow Stem Cell Transplantation Conference, opening on September 16 in Ho Chi Minh City.

Doctor Phu Chi Dung shared that recently, the Ho Chi Minh City Blood Transfusion - Hematology Hospital has cooperated with experts from Taiwan to apply CAR-T cell therapy to successfully treat a special case. The patient is a girl (12 years old) diagnosed with B-cell acute lymphoblastic leukemia, a high-risk group. After chemotherapy, the patient relapsed for the first time, then received a half-matched bone marrow transplant from her father but still relapsed for the second time. Doctors at the Ho Chi Minh City Blood Transfusion - Hematology Hospital have cooperated with Taiwanese experts to use CAR-T therapy (immunotherapy using the patient's own T cells that are genetically modified in the laboratory to have the ability to recognize and destroy cancer cells). After more than 1 year of CAR-T cell transfusion, the patient's health is currently stable and is still being treated and monitored at the Ho Chi Minh City Blood Transfusion - Hematology Hospital. This is the first case in Vietnam to apply CAR-T cell therapy to treat blood cancer.

CAR-T immunotherapy, also known as CAR-T cell therapy, is considered the biggest breakthrough in the field of cancer treatment, especially blood cancer. This method has many outstanding advantages compared to traditional treatment methods, with few side effects, high treatment efficiency, prolonging the patient's life and significantly improving the quality of life after treatment. In particular, CAR-T therapy has the ability to create a long-term immune response, helping to reduce the risk of disease recurrence. However, the biggest challenge of CAR-T therapy today is the very high cost of treatment, the production of CAR-T cells requires complex technology and modern equipment.

Currently, Ho Chi Minh City Blood Transfusion and Hematology Hospital is actively preparing facilities, staff (doctors, nurses, certified technicians) and support from foreign experts to self-produce CAR-T cells in Vietnam. The goal is to gradually master the technology, thereby reducing treatment costs for patients. Doctor Phu Chi Dung estimates that if CAR-T cells can be self-produced in Vietnam, treatment costs can be reduced by about 20 times compared to going abroad for treatment (down to less than 500 million VND/case).

In addition, at the 3 conferences this year, there are more than 200 reports by experts in the field of blood transfusion and hematology from Vietnam and internationally. The reports are the latest scientific research, focusing on main contents such as: blood transfusion, hematological diseases, chemotherapy, hematopoietic stem cell transplantation, targeted therapy, cell therapy, gene therapy, monoclonal antibodies, infections, stem cell banks, mesenchymal stem cells, blood banks, quality management, nursing...

Taking place from September 16 to 20, the 8th Vietnam Blood Transfusion - Hematology Conference, the 8th Vietnam - France Open Blood Transfusion - Transplantation - Cell Therapy Conference and the 30th Asia - Pacific Blood and Bone Marrow Stem Cell Transplantation Conference attracted the participation of nearly 2,000 delegates, including nearly 350 international delegates.

baotintuc.vn

Source: https://baolaocai.vn/lan-dau-tien-dieu-tri-thanh-cong-benh-ung-thu-mau-bang-lieu-phap-te-bao-mien-dich-car-t-post882230.html